IPE	uplica	PART B-	FEE(S) TRAN	ISMITTAL		
Complete and send (theorm, together wi		i), to: <u>Mail</u>	Mail Stop ISSUI Commissioner fo P.O. Box 1450		
DEC 0 5 2005 W OUT OF EAX				Alexandria, Virginia 22313-1450 (571) 273-2885		
INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated balls purposed below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee north-current order.						
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) 23913 7590 08/30/2005				Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.		
PFIZER INC 150 EAST 42ND STREET 5TH FLOOR - STOP 49 NEW YORK, NY 10017-5612				Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on/the date indicated below.		
NEW TORK, NT 1001753012				Peter I. Bernstein (Depositor's name) (Signature)		
				November	30, 2005	(Date)
APPLICATION NO.	FILING DATE	FIRS	T NAMED INVENT	TOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/617,967 07/10/2003 Willard M. Welch TITLE OF INVENTION: 4-(2-PYRIDYL)PIPERAZINES HAVING SHT7 RECEPTOR AGONIST ACTIV					PC11002B	4135
APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUI	BLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	-	\$300	\$1700	11/30/2005
EXAMINER A		ART UNIT	CL/	ASS-SUBCLA SS	}	
BERNHARDT, EMILY B 1624 544-363						
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 1. Change of correspondence address or indication of "Fee Address" (37 Change of Correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. 1. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. 2. For priming on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorneys or agent) and the names of up to 2 registered attorneys or agent) and the names of up to 2 registered attorneys or agents. If no name is lighted, no name will be primed.						
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)						
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.						
(A) NAME OF ASSIGNEE Pfizer, Inc. Pfizer Products, Inc. (B) RESIDENCE: (CITY and STATE OR COUNTRY) New York, New York Groton, Connecticut						
Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government						
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):						
Issue Fee Publication Fee (No s	small entity discount permitte		card. Form PTO-2038 is attached.			
				nereby authorized by charge the required fee(s), or credit any overpayment, to mber 19-1013/SSMP(enclose an extra copy of this form).		
5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).						
The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.						
Authorized Signature Park Signature November 30, 2005 5						
Typed or printed name _	Peter I. Be	mstein	<u>_</u>	Registration	No. <u>4</u> 3,497	000 167 75%
This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering; preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control numbers.						
Under the Paperwork Reduc	TION ACT OT 1995, NO persons	are required to respond	to a confection of	mornanon uniess II (mayraya a vania Civid condo	60 G
TOL-85 (Rev. 07/05) Approved for use through 04/30/2007. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT-OF COMMERCE						